Hey S.G If you combine that statement with this article ( http://www.biopharma-reporter.com/U...he-Biomanufacturing-investment-key-for-growth ) helps to support what management is telling us.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress